Self-assessment of itching/pruritus using VAS before and after alemtuzumab treatment
. | n . | Baseline VAS median (range) . | End-of-treatment VAS median (range) . |
|---|---|---|---|
| All patients | 17 | 8 (1-10) | 2 (0-9) |
| Responders | 11 | 8 (6-10) | 1 (0-6) |
| Nonresponders | 6 | 6 (1-9) | 5 (0-10) |
. | n . | Baseline VAS median (range) . | End-of-treatment VAS median (range) . |
|---|---|---|---|
| All patients | 17 | 8 (1-10) | 2 (0-9) |
| Responders | 11 | 8 (6-10) | 1 (0-6) |
| Nonresponders | 6 | 6 (1-9) | 5 (0-10) |
VAS severity: 0 indicates no itching; 10, worst possible itching.